Drug details

Rinvoq (upadacitinib extended-release tablets)

type of DMARDs, JAK Inhibitors

Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

This drug may have the following side effects:

• nausea,
• loss of appetite,
• itching,
• dark urine,
• rash,
• vomiting,
• fever,
• pale skin,
• stomach pain,
• fainting,
• unusual tiredness,
• severe stomach pain,
• severe dizziness, and
• trouble breathing
• fast heartbeat,
• severe dizziness,
• severe nausea or vomiting,
• yellowing eyes or skin (jaundice),
• swelling of the face, tongue, throat,

The following drugs are related to Rinvoq, either as a replacement or used together:

• Orencia (abatacept)
• Abrilada (adalimumab-afzb injection, for subcutaneous use)
• Cibinqo (abrocitinib tablets)
• Hadlima (adalimumab-bwwd injection)
• Arava (leflunomide)
• Arthrotec (diclofenac sodium, misoprostol)
• Olumiant (baricitinib tablets)
• Beser (fluticasone propionate lotion)
• Celebrex (celecoxib)
• Duexis (ibuprofen and famotidine tablets)
• Eticovo (etanercept injection)
• Simponi Aria (golimumab for infusion)
• Simponi Injection (golimumab injection)
• Motrin (ibuprofen)
• Indocin (indomethacin)
• Indocin IV (indomethacin inj)
• Indocin Oral Suspension (indomethacin oral suspension)
• Indocin SR (indomethacin extended release capsules)
• Mobic (meloxicam)
• RediTrex (methotrexate injection)
• Vimovo (naproxen and esomeprazole magnesium delayed release tablets)
• Skyrizi (risankizumab-rzaa injection)